TKNO icon

Alpha Teknova

4.48 USD
-0.27
5.68%
At close Aug 25, 4:00 PM EDT
After hours
4.40
-0.08
1.79%
1 day
-5.68%
5 days
1.59%
1 month
-13.51%
3 months
-23.68%
6 months
-34.88%
Year to date
-46.15%
1 year
-11.29%
5 years
-82.08%
10 years
-82.08%
 

About: Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.

Employees: 173

0
Funds holding %
of 7,429 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

333% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 6

20% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 20

18% more capital invested

Capital invested by funds: $31.7M [Q1] → $37.5M (+$5.77M) [Q2]

3% more funds holding

Funds holding: 64 [Q1] → 66 (+2) [Q2]

2.85% more ownership

Funds ownership: 11.45% [Q1] → 14.3% (+2.85%) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

Research analyst outlook

We haven’t received any recent analyst ratings for TKNO.

Financial journalist opinion

Based on 3 articles about TKNO published over the past 30 days

Neutral
Seeking Alpha
2 weeks ago
Alpha Teknova, Inc. (TKNO) Q2 2025 Earnings Call Transcript
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Matthew C. Lowell - Chief Financial Officer Stephen Gunstream - President, CEO & Director Conference Call Participants Brendan Mychal Smith - TD Cowen, Research Division Matthew Moriarty Parisi - KeyBanc Capital Markets Inc., Research Division Matthew Richard Larew - William Blair & Company L.L.C.
Alpha Teknova, Inc. (TKNO) Q2 2025 Earnings Call Transcript
Positive
The Motley Fool
2 weeks ago
Alpha Teknova (TKNO) Q2 Revenue Jumps 7%
Alpha Teknova (TKNO -0.46%), a specialist in custom bioprocess solutions for the life sciences sector, released its results on August 7, 2025. The most important news: Revenue (GAAP) rose by 7%, reaching $10.3 million, and net loss per share (GAAP) narrowed to $0.07, both of which (GAAP) surpassed market expectations.
Alpha Teknova (TKNO) Q2 Revenue Jumps 7%
Neutral
GlobeNewsWire
2 weeks ago
Teknova Reports Second Quarter 2025 Financial Results
Second quarter 2025 total revenue was $10.3 million, up 7% from prior year Achieves four consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025.
Teknova Reports Second Quarter 2025 Financial Results
Neutral
GlobeNewsWire
1 month ago
Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025
HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market.
Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025
Neutral
Seeking Alpha
3 months ago
Alpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call Transcript
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President, Marketing Stephen Gunstream - President and Chief Executive Officer Matt Lowell - Chief Financial Officer Conference Call Participants Anna Snopkowski - KeyBanc Matt Hewitt - Craig-Hallum Capital Group Matt Larew - William Blair Chad Wiatrowski - TD Cowen Operator Good day, and thank you for standing by. Welcome to the Teknova First Quarter 2025 Financial Results Conference Call.
Alpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
3 months ago
Teknova Reports First Quarter 2025 Financial Results
First quarter 2025 total revenue was $9.8 million, up 5% from prior year Company introduced proprietary PluriFreeze™  cryopreservation system, in collaboration with Pluristyx, Inc. Company reaffirms 2025 revenue guidance of $39-42 million
Teknova Reports First Quarter 2025 Financial Results
Neutral
GlobeNewsWire
4 months ago
Teknova to Report First Quarter 2025 Financial Results on May 8, 2025
HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, following the close of market.
Teknova to Report First Quarter 2025 Financial Results on May 8, 2025
Neutral
GlobeNewsWire
5 months ago
Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies
HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx's PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova.
Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies
Neutral
GlobeNewsWire
5 months ago
Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies
Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx's Novel PluriFreeze™ Cryopreservation System Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx's Novel PluriFreeze™ Cryopreservation System
Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies
Neutral
Seeking Alpha
5 months ago
Alpha Teknova, Inc. (TKNO) Q4 2024 Earnings Call Transcript
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q4 2024 Earnings Call March 4, 2025 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President, Marketing Stephen Gunstream - President and Chief Executive Officer Matt Lowell - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Matthew Parisi - KeyBanc Capital Markets Mark Massaro - BTIG Matt Hewitt - Craig-Hallum Operator Thank you for standing by, and welcome to Teknova's Fourth Quarter and Full Year 2024 Earnings Conference Call. [Operator Instructions] I would now like to hand the call over to Jennifer Henry, Senior Vice President of Marketing.
Alpha Teknova, Inc. (TKNO) Q4 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™